Blood · 2026
Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zwaan C Michel, Tasian Sarah K, Aplenc Richard, Brodersen Lisa E, Buldini Barbara, De Moerloose Barbara, Dworzak Michael N, Fogelstrand Linda, Gibson Brenda E S, Goemans Bianca F, Hasle Henrik, Hirsch Betsy A, Kaspers Gertjan J L, Klusmann Jan-Henning, Kutny Matthew A, Lehrnbecher Thomas, Locatelli Franco, Meshinchi Soheil, Petit Arnaud, Pigazzi Martina, Tierens Anne, Kolb E Anders, Reinhardt Dirk, Tomizawa Daisuke, Cooper Todd M
Аннотация
The European LeukemiaNet has periodically issued guidelines for the diagnosis and management of acute myeloid leukemia (AML) in adults. These consensus recommendations, most recently updated in 2022, incorporate recent advances in genomic testing, disease detection methods, target identification, and response assessment. Although similarities exist between AML in children and adults, pediatric AML is frequently characterized by unique cytogenetic and molecular features, which require distinct genetic and immunophenotypic diagnostics, therapeutic approaches, response assessment criteria, and supportive care strategies. To address these specific needs, an international panel of pediatric hematologist-oncologists, biologists, geneticists, and laboratory medicine scientists convened to develop recommendations for the diagnosis and management of AML in children, adolescents, and young adults (hereafter termed pediatric AML) that are discussed in this special report.